TNF Pharmaceuticals Licenses LightSolver's Compute Accelerator Tech for Innovative Therapies.
PorAinvest
martes, 2 de septiembre de 2025, 12:49 pm ET1 min de lectura
TNFA--
LightSolver, recognized as a 2025 World Economic Forum Technology Pioneer and a sample vendor in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies, has developed the first laser-based processing unit (LPU) designed to outperform quantum and supercomputing technologies. The LPU harnesses light for computation, offering an accelerated method to solve complex problems at the speed of light.
TNF Pharmaceuticals, under the leadership of Executive Chairman Joshua Silverman, has secured exclusive rights to use LightSolver’s LPU technology in cryptocurrency and blockchain applications. The company intends to change its name to reflect this new venture. TNF Pharmaceuticals aims to leverage this technology to create a more sustainable cryptocurrency infrastructure.
The partnership also involves a $7.0 million private placement financing, with TNF’s largest stockholder and other existing stockholders participating in the sale of 7,000 shares of its newly created Series H convertible preferred stock. The transaction is expected to close on or about September 4, 2025, subject to customary closing conditions.
TNF Pharmaceuticals, which focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through its MYMD-1 and Supera-CBD platforms, sees this partnership as an opportunity to capitalize on the growing momentum behind photonic computing and the future of cryptocurrency infrastructure. The company believes it has secured first-mover advantages in a burgeoning industry, positioning itself for growth and value creation.
References:
[1] https://www.businesswire.com/news/home/20250902945912/en/TNF-Pharmaceuticals-Secures-Exclusive-Global-Rights-to-Innovative-Light-Speed-Computing-Accelerator-for-Use-in-Cryptocurrency-Applications
TNF Pharmaceuticals has entered into a licensing agreement with LightSolver for their innovative compute accelerator technology. The biopharmaceutical company focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through two therapeutic platforms: MYMD-1 and Supera-CBD. MYMD-1 regulates the immune system to control TNF-a, while Supera-CBD is a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy.
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) has entered into a licensing agreement with LightSolver Ltd. to utilize the company's innovative light-speed computing accelerator technology. This strategic partnership aims to revolutionize cryptocurrency applications by significantly reducing energy costs and enhancing computational efficiency.LightSolver, recognized as a 2025 World Economic Forum Technology Pioneer and a sample vendor in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies, has developed the first laser-based processing unit (LPU) designed to outperform quantum and supercomputing technologies. The LPU harnesses light for computation, offering an accelerated method to solve complex problems at the speed of light.
TNF Pharmaceuticals, under the leadership of Executive Chairman Joshua Silverman, has secured exclusive rights to use LightSolver’s LPU technology in cryptocurrency and blockchain applications. The company intends to change its name to reflect this new venture. TNF Pharmaceuticals aims to leverage this technology to create a more sustainable cryptocurrency infrastructure.
The partnership also involves a $7.0 million private placement financing, with TNF’s largest stockholder and other existing stockholders participating in the sale of 7,000 shares of its newly created Series H convertible preferred stock. The transaction is expected to close on or about September 4, 2025, subject to customary closing conditions.
TNF Pharmaceuticals, which focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through its MYMD-1 and Supera-CBD platforms, sees this partnership as an opportunity to capitalize on the growing momentum behind photonic computing and the future of cryptocurrency infrastructure. The company believes it has secured first-mover advantages in a burgeoning industry, positioning itself for growth and value creation.
References:
[1] https://www.businesswire.com/news/home/20250902945912/en/TNF-Pharmaceuticals-Secures-Exclusive-Global-Rights-to-Innovative-Light-Speed-Computing-Accelerator-for-Use-in-Cryptocurrency-Applications
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios